Intraocular Bevacizumab (Avastin) for Rubeosis Iridis

Summary

Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers. Bevacizumab may have a role in treating ocular disorders involving fibrovascular proliferation. To determine whether intraocular bevacizumab decreases rubeosis iridis in patients with neovascular glaucoma.

Timeline

Start

2006-11

Primary completion

2011-10

Completion

2011-11

Drugs

Indications